Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$5.70 USD
-0.10 (-1.72%)
Updated May 31, 2024 04:00 PM ET
After-Market: $5.68 -0.02 (-0.35%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Ocular Therapeutix, Inc. [OCUL]
Reports for Purchase
Showing records 21 - 40 ( 87 total )
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
1Q22 Financial Results Reported; Reiterate Buy; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Mixed Results in Phase 2 Short-Term Dry Eye Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
OTX-CSI Phase 2 Chronic Dry Eye Trial Setback; Lowering PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
DEXTENZA Label Expanded With Allergic Conjunctivitis; Raising PT to $18
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Solid 2Q21 Sales; Multiple Clinical Catalysts; Upgrading to Buy with $17 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
OTX-TKI U.S. Wet AMD Trial Starts Patient Dosing; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Preliminary 2Q21 Revenue Reported: Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Discovery Partnership in Dry AMD Established: Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
1Q21 Financial Results; Moderate Revenue Miss; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Highlights from wAMD Key Opinion Leader Call: Treat and Extend; Once and Done
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
2020 Financial Results Reported: Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
DEXTENZA Supplemental NDA Submitted; Financing Closed; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Robust Top-Line Growth in 3Q20; Reiterate Buy; Raising PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
DEXTENZA and OTX-TIC Rights Out-Licensed for Multiple Asian Regions; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
OTX-CSI Improves Dry Eye Disease in Phase 1 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Preliminary 3Q20 Product Revenue Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
First Patients Dosed in OTX-CSI Phase 2 Dry Eye Study; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y